Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics'...

[cafead]

via The FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet next Tuesday to discuss whether Cytokinetics’ potential heart drug can safely reduce the risk of cardiovascular death and heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction.

article source